Form 4: Protagonist Therapeutics Director Sells Shares Under 10b5-1 Plan

Protagonist Therapeutics Director William D. Waddill sold 4,000 shares of common stock for $59.25 per share under a pre-arranged trading plan.

Summary

• William D. Waddill, a Director of Protagonist Therapeutics, Inc. (PTGX), executed a sale of common stock.
• The transaction involved the disposition of 4,000 shares of PTGX common stock.
• The shares were sold at a price of $59.25 per share.
• The sale was conducted on August 27, 2025.
• This transaction was made pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Waddill on November 10, 2023.
• Following this transaction, William D. Waddill directly beneficially owns 9,130 shares of Protagonist Therapeutics common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a director selling shares. While the 10b5-1 plan mitigates the immediate negative implications, insider selling is generally not viewed as a positive indicator for future stock performance.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned disposition rather than a reaction to immediate, non-public information.

Negatives

• A director selling shares can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects, even when pre-planned.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders may interpret the director's sale as a signal, potentially influencing their perception of the company's value or future prospects.

Key Dates

Recommendation

While a director's sale of shares, even under a pre-arranged 10b5-1 plan, is not an overtly positive signal, it does not necessarily warrant a 'sell' recommendation without further fundamental analysis. The pre-planned nature suggests it's not based on immediate adverse news. Investors should 'hold' and monitor future company performance and additional insider activity, as this single transaction alone is not a strong indicator for a significant change in investment thesis.

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Sale, Director, William D. Waddill, 10b5-1 Plan